Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: A large cohort analysis

Chest

Volumn 149, Issue 5, 2016, Pages 1205-1214

  Moua, Teng ^a   Westerly, Blair D ^a   Dulohery, Megan M ^a   Daniels, Craig E ^a   Ryu, Jay H ^a   Lim, Kaiser G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute respiratory decline; Fibrotic interstitial lung disease; Hospitalization

Indexed keywords

ACUTE RESPIRATORY TRACT DISEASE; ACUTE RESPIRATORY WORSENING; ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FIBROSING ALVEOLITIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERCAPNIA; HYPOXEMIA; IN HOSPITAL MORTALITY; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTDISCHARGE MORTALITY; PRIORITY JOURNAL; SURVIVAL; ACUTE DISEASE; ARTIFICIAL VENTILATION; COMPLICATION; FORCED EXPIRATORY VOLUME; HOSPITAL MORTALITY; HYPOXIA; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; LENGTH OF STAY; LUNG DIFFUSION CAPACITY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOPHYSIOLOGY; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TOTAL LUNG CAPACITY; UTILIZATION; VERY ELDERLY; VITAL CAPACITY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPERCAPNIA; HYPOXIA; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; LENGTH OF STAY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 84966614893     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2015.12.026     Document Type: Article

References (19)

1. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-643.
2. Tachikawa R, Tomii K, Ueda H, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration. 2012;83(1):20-27.
3. Hozumi H, Nakamura Y, Johkoh T, et al. Acute exacerbation in rheumatoid arthritis-Associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3(9):e003132.
4. Hariri LP, Mino-Kenudson M, Shea B, et al. Distinct histopathology of acute onset or abrupt exacerbation of hypersensitivity pneumonitis. Hum Pathol. 2012;43(5):660-668.
5. Park IN, Kim DS, Shim TS, Lee JS, Nicholson AG, Colby T. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214-220.
6. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143-150.
7. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2): 356-363.
8. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128(5): 3310-3315.
9. Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J. 2008;32(1):170-174.
10. Oda K, Ishimoto H, Yamada S, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014;15:109.
11. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med. 2002;166(6): 839-842.
12. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
13. Singh B, Singh A, Ahmed A, et al. Derivation and validation of automated electronic search strategies to extract Charlson comorbidities from electronic medical records. Mayo Clin Proc. 2012;87(9):817-824.
14. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet Investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.
15. Brown AW, Fischer CP, Shlobin OA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147(1):173-179.
16. Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ; IPFnet Investigators. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest. 2014;146(5):1256-1262.
17. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
18. King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
19. King TE Jr., Noble PW, Bradford WZ. Treatments for idiopathic pulmonary fibrosis. N Engl J Med. 2014;371(8):783-784.